Sanofi's Nirsevimab Reduced Infant Hospitalizations for RSV by 83% in Real-World Study
Sanofi announced that its nirsevimab medication reduced hospitalizations due to RSV-related lower respiratory tract infections in infants by 83.2% in a real-world clinical trial setting.
Sanofi reported on May 12, 2023, that its nirsevimab, a preventive measure against Respiratory Syncytial Virus (RSV), resulted in an 83.2% reduction in hospitalizations for RSV-related lower respiratory tract disease (LRTD) in infants under 12 months old. These findings come from the HARMONIE Phase 3b clinical trial, which gathered data in real-world conditions across Europe during the 2022-2023 RSV season.
The HARMONIE study involved over 8,000 infants at nearly 250 sites in France, Germany, and the United Kingdom. The trial was designed to assess the efficacy and safety of a single intramuscular dose of nirsevimab when administered to infants.
"This winter saw higher rates of RSV-related infant hospitalizations than during pandemic or pre-pandemic years," stated Thomas Triomphe, Executive Vice President, Vaccines at Sanofi. "The HARMONIE data demonstrate the real-world impact nirsevimab has on pediatric hospitalizations, and illustrate its importance for infants, their families and public health."
The data also indicated that nirsevimab reduced the incidence of hospitalizations for severe RSV-related LRTD by 75.7%. Furthermore, the drug decreased the incidence of all-cause LRTD hospitalizations by 58.04%. Throughout the trial, nirsevimab maintained a favorable safety profile, consistent with earlier pivotal trial results. RSV is a leading cause of lower respiratory infections and results in significant hospitalization rates for young children annually.